MAPT and Alzheimer disease: These initial findings suggest that blood plasma markers, particularly p-tau markers, and digital cognitive markers may be used in conjunction as scalable and accessible tools to screen for AD in its earliest stages, reducing the need for expensive and invasive procedures such as PET scans, lumbar punctures, and extensive in-person cognitive batteries for individuals with minimal cognitive complaints.